As More Deadly Strains Emerge, the Post Pandemic Recovery SPAC Gears up to Finance “Long-Hauler “treatment through proposed merger with Napo EU; Interview with Lisa Conte and Andreea Porcelli

  • Home
  • Press release
  • As More Deadly Strains Emerge, the Post Pandemic Recovery SPAC Gears up to Finance “Long-Hauler “treatment through proposed merger with Napo EU; Interview with Lisa Conte and Andreea Porcelli

Lisa Conte and Andreea Porcelli were interviewed again this week on Innovators with Jane King regarding long-hauler syndrome in post-COVID-19 recovery patients and Jaguar’s plans to explore the possibility of obtaining conditional marketing authorization in Europe to support development and commercialization of crofelemer for the COVID-related indication.

When discussing post-acute COVID-19 long-hauler symptoms during a January 23, 2021 interview on MSNBC, Dr. Anthony Fauci, the Director of the National Institute of Allergy & Infectious Diseases, commented, “We had a workshop in December that my institute sponsored bringing in experts from all over the country and the world. We’re going to make a major investment in research dollars to try and find out the full extent of this… any hints towards what the underlying mechanisms are… what we can do to treat it. We take it very seriously for the simple reason that even if a small fraction, and it appears to be more than just a small fraction of people, have persistent symptoms, when you look at the 24, 25 million people in the United States who’ve been infected – or be it not all of them have had any symptoms – but even those who have symptoms – and globally, when you have approaching a 100 million people having been infected, this could be something that really could be an issue and that’s the reason why we’re taking it very seriously.”

 

Leave A Comment

Subscribe to our newsletter

Sign up to receive latest news, updates, promotions, and special offers delivered directly to your inbox.
No, thanks